GlaxoSmithKline's Benlysta Gets FDA Approval for Lupus Nephritis
December 17 2020 - 9:57AM
Dow Jones News
By Michael Dabaie
GlaxoSmithKline PLC said the U.S. Food and Drug Administration
approved Benlysta for adult patients with active lupus nephritis
receiving standard therapy.
The approval extends the current indication in the U.S. to
include both systemic lupus erythematosus and lupus nephritis for
the intravenous and subcutaneous formulations.
Lupus nephritis is a serious inflammation of the kidneys caused
by systemic lupus erythematosus, the most common form of lupus,
which can lead to end-stage kidney disease, requiring dialysis or a
kidney transplant, the company said.
GlaxoSmithKline American depositary receipts were up 1.8% to
$37.55 premarket Thursday.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
December 17, 2020 09:42 ET (14:42 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Jun 2024 to Jul 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Jul 2023 to Jul 2024
